BRAIN Initiative: Brain-Behavior Quantification and Synchronization Transformative and Integrative Models of Behavior at the Organismal Level (U01 Clinical Trials Not Allowed)
(RFA-DA-24-041)
This Brain-Behavior Quantification and Synchronization notice of funding opportunity (NOFO) seeks applications using non-human animal models that bring together transdisciplinary teams and aim to 1) develop, validate, and apply cutting-edge tools and methods for minimally invasive, multi-dimensional, high-resolution measurement of behavior at the organismal level, with synchronous capture of data from the dynamic environment of the organism; 2) develop advanced analytic approaches to integrate multidimensional behavioral, neural and environmental data; and 3) develop and test new theoretical and computational models aiming to advance understanding of behavior as a complex dynamic system. Proposed projects are expected to be designed with the capacity to integrate synchronously recorded neural data and/or inform existing models of neurobehavioral function, such as those developed with the support of the NIH BRAIN Initiative. This NOFO is intended for applications using non-human animal models.  Applicants proposing research involving humans or use of human subjects data as a significant component should submit under the companion NOFO RFA-DA-24-040.

Establishing a Center for the Advancement of Substance Use Disorder (SUD) Pharmacotherapeutics (U54 Clinical Trials Not Allowed)
(RFA-DA-25-056)
The purpose of this notice of funding opportunity (NOFO) is to establish a Center that educates and mentors researchers in formal product development for new substance use disorder (SUD) pharmacotherapeutics and to advance the best concepts through initial experiments via technical and financial support. 


Early-Stage Dissemination and Implementation Research in Communication Disorders (R21 Clinical Trial Optional)
(RFA-DC-24-008)
NIDCD invites applications for early-stage dissemination and implementation (D&I) research projects in the NIDCD mission areas of hearing, balance, taste, smell, voice, speech, and language.

NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
(PAR-24-208)
This Notice of Funding Opportunity Announcement (NOFO) solicits cooperative agreement (UG3/UH3) applications for implementation of investigator-initiated, single or multi-site, interventional clinical trials (all phases). Investigators who have completed all necessary preparation (e.g., the trial design, protocol synopsis, data analysis plan, etc.) through other means may apply for a NIAMS UG3/UH3. The UG3 phase is designed to allow the investigators to prepare the final aspects needed to start the trial, (e.g., establishing the single IRB (sIRB), contracts and reliance agreements with sites, hiring of staff, etc.). Transition to the UH3 phase to begin the trial is dependent upon completion of the UG3 milestones proposed by the investigator and approved by NIAMS. UG3 projects that meet their milestones will be administratively considered by NIAMS and prioritized for transition to the UH3 phase. NIAMS expects trials to be hypothesis-driven and have the potential for high clinical impact within the research mission of NIAMS.

Single Source: NINDS Exploratory Clinical Trials (U01 Clinical Trial Required)
(PAR-24-215)
This is a non-competitive funding opportunity intended  to fund a single award. The National Institute of Neurological Disorders and Stroke is announcing its intent to issue a single source cooperative agreement  to the Hennepin Healthcare Research Institute to submit a renewal application to complete  the phase II Hyperbaric Oxygen Brain Injury Treatment (HOBIT) clinical trial.   

SBIR E-Learning for HAZMAT and Emergency Response (R43/R44 Clinical Trial Not Allowed)
(RFA-ES-24-003)
This Notice of Funding Opportunity Announcement (NOFO) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to further the development of Technology-Enhanced Training Products for the health and safety training of hazardous materials (HAZMAT) workers; waste treatment personnel; skilled support personnel associated with an emergency/disaster; emergency responders in biological hazard response, infectious disease response, and medical waste cleanup; emergency responders in disasters; and worker resiliency training. Technology-Enhanced Training Products as defined by the Worker Training Program (WTP) include, but are not limited to, supporting training through various venues such as online training, mobile device training, augmented reality (AR), virtual reality (VR), and serious gaming. These advanced technologies complement all phases of training that can enhance, supplement, improve, and provide health and safety training for hazardous materials workers. These products must complement the goals and objectives of the WTP. The major objective of the NIEHS WTP is to prevent work related harm by training workers in how best to protect themselves and their communities from exposure to hazardous materials. The financial support for this initiative comes directly from NIEHS Worker Education and Training Branch SBIR funds.

NINDS Research Education Opportunities (R25 Clinical Trial Not Allowed)
(PAR-24-200)
The purpose of this notice of funding opportunity (NOFO) is to encourage applications for the initiation or continuation of nationally available neuroscience research education programs that will significantly advance the mission of NINDS. The primary focus of programs submitted under this NOFO should be on intensive hands-on experience that will provide research experience, an in-depth understanding of techniques, analytic approaches and theory, and expertise that is only possible from a nationally organized program. Within the context of gaining expertise primarily through hands-on experience, programs must also include immersive coursework and expert discussion when appropriate. Programs appropriate for this NOFO must include a nationwide recruitment process to encourage applications from prospective participants and an established application and selection process.

Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Trials Optional)
(PAR-24-207)
This initiative will support multi-level and/or multi-domain intervention research to reduce disparities in liver diseases and liver cancer among populations who experience health disparities in the United States (U.S.).

Access and Manipulation of Brain Cell Subtypes Implicated in Aging and AD/ADRD (R61/R33 Clinical Trial Not allowed)
(RFA-AG-25-024)
This Notice of Funding Opportunity (NOFO) invites applications proposing innovative strategies to target and manipulate brain cell subtypes that are altered in aging, Alzheimer's Disease (AD), and AD-Related Dementias (ADRDs). ADRDs include frontotemporal disorders (FTD), Lewy body dementia (LBD), vascular contributions to cognitive impairment and dementia (VCID), and multiple etiology dementias (MED). 

Lasker Clinical Research Scholars Program (Si2/R00 Clinical Trial Optional)
(PAR-24-202) This NOFO encourages applications for the Lasker Clinical Research Scholars Program for the purpose of supporting the research activities during the early stage careers of independent clinical researchers. The program offers the opportunity for a unique bridge between the NIH intramural and extramural research communities and contains two phases. In the first phase, Lasker Scholars will receive appointments for up to 5-7 years as tenure-track investigators within the NIH Intramural Research Program with independent research budgets. In the second phase, successful scholars will receive up to 3 years of NIH support for their research at an extramural research facility; or, the Scholar can be considered to remain as an investigator within the intramural program.

Minor Use Minor Species Development of Drugs (R01)
(PAR-24-216)
This Notice of Funding Opportunity (NOFO) is issued by the Food and Drug Administration (FDA), Center for Veterinary Medicine (CVM), and solicits Research Project (R01) grant applications from institutions or organizations that propose to develop or support the development of designated new animal drugs intended for minor uses in major species or for use in minor species (MUMS). 

Type 1 Diabetes TrialNet Clinical Network Hub (U01 Clinical Trial Not Allowed)
(RFA-DK-25-005)
The purpose of this Notice of Funding Opportunity (NOFO) is to continue support for the Type 1 Diabetes TrialNet Clinical Network Hub (HUB), a screening and clinical activities coordination unit for clinical trials focusing on the prevention of and early intervention in type 1 diabetes (T1D). The main objective of the HUB is to increase the efficiency and productivity of the TrialNet network by providing coordination of communications and outreach and developing new tools and approaches to increase screening, recruitment and retention. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

Research Forrest